Pulse Biosciences (NASDAQ:PLSE) Upgraded to Sell at StockNews.com

StockNews.com upgraded shares of Pulse Biosciences (NASDAQ:PLSE) to a sell rating in a report issued on Thursday morning.

Pulse Biosciences Trading Up 1.6 %

NASDAQ PLSE opened at $11.19 on Thursday. The firm’s fifty day simple moving average is $10.06 and its two-hundred day simple moving average is $9.55. Pulse Biosciences has a 12-month low of $3.78 and a 12-month high of $14.96. The firm has a market capitalization of $617.97 million, a P/E ratio of -13.81 and a beta of 1.76.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Tuesday, May 7th. The company reported ($0.17) EPS for the quarter.

Insider Transactions at Pulse Biosciences

In related news, CEO Burke Thomas Barrett acquired 10,000 shares of the stock in a transaction dated Monday, May 20th. The stock was acquired at an average cost of $8.56 per share, for a total transaction of $85,600.00. Following the completion of the purchase, the chief executive officer now owns 10,000 shares of the company’s stock, valued at approximately $85,600. The purchase was disclosed in a document filed with the SEC, which is available through this link. Insiders own 71.50% of the company’s stock.

Institutional Investors Weigh In On Pulse Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the stock. BNP Paribas Financial Markets lifted its position in Pulse Biosciences by 63.6% during the first quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company’s stock valued at $66,000 after purchasing an additional 2,952 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in Pulse Biosciences during the first quarter valued at $88,000. Inspire Investing LLC lifted its position in Pulse Biosciences by 32.1% during the first quarter. Inspire Investing LLC now owns 41,358 shares of the company’s stock valued at $360,000 after purchasing an additional 10,039 shares during the period. Cetera Advisors LLC acquired a new position in Pulse Biosciences during the first quarter valued at $109,000. Finally, PNC Financial Services Group Inc. acquired a new position in Pulse Biosciences during the fourth quarter valued at $242,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.